menu

Navigating the Flu Season During the Coronavirus Pandemic

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Navigating the Flu Season During the Coronavirus Pandemic

Program Information
Recommended

Program Information

ReachMD Healthcare Image
RestartResume

How can we help prepare for the flu amid the ongoing COVID-19 pandemic?

  • Sponsored by

  • Overview

    With the ongoing COVID-19 pandemic threatening our health and adding burden to our healthcare system, it’s more important than ever to educate patients on the flu and its symptoms. Here to share tips on how we can help prepare for, diagnose and treat flu this season are Dr. Casey Lafferty and Physician Assistant Doctorate Dr. Eder Hernández.

    This information is intended for US audiences only.

  • Important Safety Information

    Xofluza Indication:

    XOFLUZA is an influenza virus polymerase acidic (PA) endonuclease inhibitor indicated for:

    • Treatment of acute uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours and who are:       

                      ○       Otherwise healthy, or;

                      ○       At high risk of developing influenza related complications

    • Post-exposure prophylaxis (PEP) of influenza in patients 12 years of age and older following contact with an individual who has influenza

    Limitations of Use

    Influenza viruses change over time, and factors such as the virus type or subtype, emergence of resistance, or changes in viral virulence could diminish the clinical benefit of antiviral drugs. Consider available information on drug susceptibility patters for circulating influenza virus strains when deciding whether to use XOFLUZA.

    Important Safety Information

    Contraindications

    XOFLUZA is contraindicated in patients with a history of hypersensitivity to baloxavir marboxil or any of its ingredients. Serious allergic reactions have included anaphylaxis, angioedema, urticaria, and erythema multiforme.

    Warning and Precautions

    • Hypersensitivity: Cases of anaphylaxis, urticaria, angioedema, and erythema multiforme have been reported in post marketing experience with XOFLUZA. Appropriate treatment should be instituted if an allergic-like reaction occurs or is suspected.
    • Risk of Bacterial Infections: There is no evidence of the efficacy of XOFLUZA in any illness caused by pathogens other than influenza viruses. Serious bacterial infections may begin with influenza-like symptoms or may coexist with, or occur as, a complication of influenza. XOFLUZA has not been shown to prevent such complications. Prescribers should be alert to potential secondary bacterial infections and treat them as appropriate.

    Adverse Reactions

    • The most common adverse reactions (≥ 1%) in clinical studies for acute uncomplicated influenza were diarrhea (3%), bronchitis (3%), nausea (2%), sinusitis (2%), and headache (1%).
    • The most common adverse reactions (≥ 1%) in clinical studies for PEP was nasopharyngitis (6%).

    Drug Interactions

    • Polyvalent cations: Co-administration with polyvalent cation-containing products may decrease plasma concentrations of baloxavir, which may reduce XOFLUZA efficacy. Avoid co-administration of XOFLUZA with dairy products, calcium-fortified beverages, polyvalent cation-containing laxatives or antacids, or oral supplements (e.g., calcium, iron, magnesium, selenium, or zinc).
    • Vaccines: The concurrent use of XOFLUZA with intranasal live attenuated influenza vaccine (LAIV) has not been evaluated. Concurrent administration of antiviral drugs may inhibit viral replication of LAIV and thereby decreases the effectiveness of LAIV vaccination. Interactions between inactivated influenza vaccines and XOFLUZA have not been evaluated.

    For additional important safety information, please see XOFLUZA full Prescribing Information and visit www.XOFLUZA.com.

    You are encouraged to report side effects to Genentech by calling 1-888-835-2555 or to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.

Schedule15 Oct 2021